The most common cancer in women — and one of the deadliest — may have finally met its match. Development of a breakthrough ...

By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

A groundbreaking vaccine, potentially capable of eradicating breast cancer by 2030, has shown a strong immune response in over 75% of women during its phase one clinical trial.

At the crossroads of innovation and equity, Josette Gbemudu and Merck are helping rewrite the narrative for breast cancer ...

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

New research presented at the 2025 American Society for Clinical Oncology’s (ASCO) annual meeting has shed light on the ...

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

The "Fore The Fight: One Tough Titty Charity Golf Outing" is June 20 at Boulder Creek Golf Club. Foursomes can still sign up ...

More than 100 cancer survivors gathered at Fiddler's Green on Sunday morning to mark National Cancer Survivors Day with ...